CoChat

Inhibition of Cyclic GMP ‐ AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1 ‐Deficient Mice

An, Jie, Woodward, Joshua J., Lai, Weinan, Minie, Mark, Sun, Xizhang, Tanaka, Lena, Snyder, Jessica M., Sasaki, Tomikazu, Elkon, Keith B. · 2018 · Arthritis & Rheumatology
Cited by 130

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objective: Type I interferon ( IFN ) is strongly implicated in the pathogenesis of systemic lupus erythematosus ( SLE ) as well as rare monogenic interferonopathies such as Aicardi‐Goutières syndrome ( AGS ), a disease attributed to mutations in the DNA exonuclease TREX 1 . The DNA ‐activated type I IFN pathway cyclic GMP ‐ AMP ( cGAMP ) synthase ( cGAS ) is linked to subsets of AGS and lupus. This study was undertaken to identify inhibitors of the DNA – cGAS interaction, and to test the lead candidate drug, X6, in a mouse model of AGS. Methods: Trex1 −/− mice were treated orally from birth with either X6 or hydroxychloroquine ( HCQ ) for 8 weeks. Expression of IFN ‐stimulated genes ( ISG s) was quantified by quantitative polymerase chain reaction. Multiple reaction monitoring by ultra‐performance liquid chromatography coupled with tandem mass spectrometry was used to quantify the production of cGAMP and X6 drug concentrations in the serum and heart tissue of Trex1 −/− mice. Results: On the basis of the efficacy‐to‐toxicity ratio established in vitro, drug X6 was selected as the lead candidate for treatment of Trex1 −/− mice. X6 was significantly more effective than HCQ in attenuating ISG expression in mouse spleens ( P < 0.01 for Isg15 and Isg20 ) and hearts ( P < 0.05 for Isg15 , Mx1 , and Ifnb, and P < 0.01 for Cxcl10 ), and in reducing the production of cGAMP in mouse heart tissue ( P < 0.05), thus demonstrating target engagement by the X6 compound. Of note, X6 was also more effective than HCQ in reducing ISG expression in vitro ( P < 0.05 for IFI 27 and MX 1 , and P < 0.01 for IFI 44L and PKR ) in human peripheral blood mononuclear cells from patients with SLE . Conclusion: This study demonstrates that X6 is superior to HCQ for the treatment of an experimental autoimmune myocarditis mediated in vivo by the cGAS /stimulator of IFN genes ( cGAS / STING ) pathway. The findings suggest that drug X6 could be developed as a novel treatment for AGS and/or lupus to inhibit activation of the cGAS / STING pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40559

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
An, J., Woodward, J. J., Lai, W., Minie, M., Sun, X., Tanaka, L., Snyder, J. M., Sasaki, T., & Elkon, K. B.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2018-09-14
Volume
70
Issue
11
Pages
1807-1819
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2803376047
Cited by
130
References
6
FWCI
3.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.